Reframe The Game: Why The Best Companies Don’t Stay In Their Lanes

Profitability and long-term relevance require stepping beyond familiar boundaries to build entirely new sources of advantage.
The Economist

The plan to rescue Denmark’s weight-loss pioneer

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...
newscase

Novo Nordisk Seeks Momentum with EMA Backing for Higher-Dose Obesity Drug

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...
Zacks Investment Research on MSN

CHMP backs higher-dose Wegovy as Novo Nordisk seeks 2026 EU approval

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...